Dose Finding and Randomized, Multicenter, Placebo-Controlled, Phase 2 Study of Enzastaurin and Sunitinib Versus Placebo and Sunitinib in Patients With Metastatic Renal Cell Carcinoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Enzastaurin (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors Eli Lilly
- 25 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated
- 30 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.